Once-daily olopatadine ophthalmic solution 0.2% in the treatment of allergic conjunctivitis and rhinoconjunctivitis

References

• Ciprandi G, Buscaglia S, Cerqueti PM, Canonica GW. Drug treatment of allergic conjunctivitis – a review of the evidence. Drugs43, 154–176 (1992).
   PubMed Web of Science ®Google Scholar
• Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits TNFα release from human conjunctival mast cells. Ann. Allergy Asthma Immunol.84, 504–508 (2000).
   PubMed Web of Science ®Google Scholar
• Ohmori K, Hayashi K, Kaise T et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn. J. Pharmacol.88, 379–397 (2002).
   PubMedGoogle Scholar
• Rosenwasser LJ, O’Brien T, Weyne J. Mast cell stabilization and antihistamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research. Curr. Med. Res. Opin.21(9), 1377–1387 (2005).
   PubMed Web of Science ®Google Scholar
• Vogelson CT, Abelson MB, Pasquine T et al. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration. Allergy Asthma Proc.25, 69–75 (2004).
   PubMed Web of Science ®Google Scholar
• Roy AK. Ocular tissue distribution of olopatadine following a single topical ocular dose of a 0.2% olopatadine ophthalmic solution to male New Zealand white rabbits. Alcon Internal Report 023:33:0502 (2002).
   Google Scholar
• Nonaka H, Ishi A, Kase H. Effect of KW-4679, a novel antiallergic agent, on histamine H1 receptor. Jpn. J. Pharmacol.108, 84–88 (1990).
   Google Scholar
• The Allergy Report: Science Based Findings on the Diagnosis and Treatment of Allergic Disorders, 1996–2001. American Academy of Allergy, Asthma and Immunology, WI, USA (2001).
   Google Scholar
• Lafuma A, Smith AF. Cost–effectiveness of olopatadine in SAC treatment. Expert Rev. Pharmacoeconomics Outcomes Res.2, 549–554 (2002).
   PubMedGoogle Scholar
• Slonim CB, Boone R. The ocular allergic response: a pharmacotherapeutic review. Formulary39, 213–222 (2004).
   Google Scholar
• Guest JF, Clegg JP, Smith AF. Health economic impact of olopatadine compared to branded and generic sodium cromoglycate in the treatment of SAC in the UK. Curr. Med. Res. Opin.22(9), 1777–1785 (2006).
   PubMed Web of Science ®Google Scholar
• Pitt AD, Smith AF, Lindsell L et al. Economic and quality-of-life impact of SAC in Oxfordshire. Ophthalmic Epidemiol.11, 17–33 (2004).
   PubMed Web of Science ®Google Scholar
• Wolters Kiluwer Health. Source®, Prescriber Data. December 2006.
   Google Scholar
• Leonardi A, Zafirakis P. Efficay and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked environmental study of patient preference. Curr. Med. Res. Opin.20, 1167–1173 (2004).
   PubMed Web of Science ®Google Scholar
• Butrus S, Greiner JV, Discepola M et al. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin. Ther.22, 1462–1472 (2000).
   PubMed Web of Science ®Google Scholar
• Katelaris CH, Ciprandi G, Missotten L et al. International olopatadine study group. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Clin. Ther.24, 1561–1575 (2004).
   Google Scholar
• Spangler DI, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.5% ophthalmic solution in the conjunctival allergen challenge model. Clin. Ther.23, 1272–1280 (2001).
   PubMed Web of Science ®Google Scholar
• Lanier BQ, Fingold I, D’Arienzo P et al. Clinical efficacy of olpatadine vs. epinastine ophthalmic solution in the conjunctival challenge model. Curr. Med. Res. Opin.20, 1227–1233 (2004).
   PubMed Web of Science ®Google Scholar
• Bensch G, Mah F, Townsend W, Rosenwasser LJ. Olopatadine 0.2% is superior to epinastine 0.05% in the prevention of itching at onset and 12 hours following conjunctival allergen challenge. Presented at: Western Society of Allergy, Asthma and Immunology 2007 Scientific Session. Wailea, HI, USA, 14–18 January 2007.
   Google Scholar
• Abelson MB, Turner D. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the sign and symptoms of SAC and rhinoconjunctivitis. Clin. Ther.25, 931–947 (2003).
   PubMed Web of Science ®Google Scholar
• Abelson MB, Gomes PJ, Vogelson CT et al. Clinical efficacy of olopatadine ophthalmic solution 0.2% compared to placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study. Clin. Ther.26, 1237–1248 (2004).
   PubMed Web of Science ®Google Scholar
• Spangler DL, Epstein AB, Mah FS. One drop olopatadine 0.2% is comparable to two drops of olopatadine 0.1% in the prevention of itching associated with allergic conjunctivitis after 24 hours. Presented at: Western Society of Allergy, Asthma and Immunology 2007 Scientific Session. Wailea, HI, USA, 14–18 January 2007.
   Google Scholar
• Abelson MB, Gomes PJ, Vogelson CT et al. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis. Curr. Med. Res. Opin.21(5), 683–691 (2005).
   PubMed Web of Science ®Google Scholar
• Lichtenstein SJ, Vogelson CT, Wells DT et al. Olopatadine is safe and well-tolerated in adults and children as young as three-years of age. Presented at: Annual meeting of the Western Society of Allergy, Asthma and Immunology. Maui, HI, USA, 18–23 January 2003.
   Google Scholar
• Prescription Drug and Diagnosis Audit. Verispan, MAT, November 2006.
   Google Scholar
• Lafuma A, Fagnani F, Nuijten M, Berdeaux G. Cost and consequences of olopatadine 0.1% versus levocabastine 0.05% in the treatment of SAC. Value Health4(6), 513 (2001).
   Google Scholar
• Lanier BQ, Gross RD, Marks BB, Cockrum PC, Juniper EF. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms. Ann. Allergy Asthma Immunol.86, 641–648 (2001).
   PubMed Web of Science ®Google Scholar
• Berger WE, Abelson MB, Gomes PJ et al. Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on QoL in patients with allergic rhinitis using systemic or nasal therapy. Ann. Allergy Asthma Immunol.95(4), 361–371 (2005).
   PubMed Web of Science ®Google Scholar
• Berdy GJ, Scoper SV, Lichtenstein SJ et al. Once-a-day olopatadine improves the health-related quality-of-life of allergic conjunctivitis patients. Presented at: American Academy of Allergy, Asthma & Immunology, San Diego, CA, USA, 24 February 2007 (Abstract).
   Google Scholar
• Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J. Clin. Epidemiol.147(1), 81–87 (1994).
   Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the association between dose regimen and medication compliance. Clin. Ther.23, 1296–1310 (2001).
   PubMed Web of Science ®Google Scholar
• Hawkins T. Impact of once-and twice-daily dosing on regimens on adherence and overall safety. AIDS Read.14, 34–36 (2004).
   Google Scholar
• Richter A, Anton SF, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin.Ther.25, 2307–2335 (2003).
   PubMed Web of Science ®Google Scholar